Company intelligence / Profile preview
Stemline Therapeutics
New York City, NY, USAstemline.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Stemline has two FDA-approved products:
- ELZONRIS® (tagraxofusp-erzs): Approved for BPDCN in adults and children ≥2 years. Also being studied for AML, CMML, MF[1][2][7].
- ORSERDU™ (elacestrant): First FDA-approved oral SERD for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy. Demonstrated positive results in the pivotal Phase III EMERALD trial[2][7]. Additional pipeline assets are at various stages of development targeting hematologic malignancies and solid tumors.
- Therapeutic areas
- OncologyHematology
- Modalities
- Targeted biologics (e.g., fusion proteins)Small molecules (e.g., oral inhibitors)Immunotherapies (peptide vaccines)
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
Tempus AI – collaboration to implement AI-enabled care pathway intelligence platform Tempus Next[7]Glofitamab combination studies with MEN1703 kinase inhibitor[9]
Beyond the preview
Go deeper on Stemline Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stemline Therapeutics.